CD19 is a B-lymphocyte cell surface molecule that functions as a general response regulator or rheostat, which defines intrinsic and B-cell antigen receptor-induced signalling thresholds that are critical for humoral immunity and expansion of the peripheral B-cell pool. In addition, B-cell responses are influenced by signals transduced through a CD19-CD21 cell surface receptor complex, where the binding of complement C3d to CD21 links humoral immune responses with the innate immune system. This review outlines recent biochemical and genetic studies that characterize the signal transduction pathways utilized by this receptor complex to regulate B-cell intracellular calcium responses.
Introduction
B-lymphocyte development and function are regulated by signals transduced through the B-cell antigen receptor (BCR). BCR engagement activates signalling pathways by distinct non-receptor protein tyrosine kinases (PTKs) including the Src-family PTKs (Lyn, Fyn, and Blk) , Syk, and the Tec-family member Btk. A fraction of cellular Lyn associates constitutively with the BCR, but Key words: complement, homoeostasis, signal transduction, tyrosine phosphorylation. Abbreviations used: BCR B-cell antigen receptor: Cay, intracellular calcium; CD I9-'-mice, CD 19-deficient mice; CD I9TG mice, transgenic mice with overexpression of CD 19: PI 3-kinase, phosphoinositide 3-kinase; PTK, protein tyrosine kinase; SHP I, SH2 domain-containing phosphotyrosine phosphatase I , 'To whom correspondence should be addressed (e-mail thornas.tedder@duke.edu).
Lyn localizes primarily to the detergent-insoluble cholesterol-rich microdomains of the plasma membrane [l] . BCR cross-linking may result in its rapid translocation into these lipid rafts, where Igcr/IgP are phosphorylated by Lyn [2] . Lyn and other Src-family PTKs play crucial roles in initiating BCR signalling, which leads to downstream activation of Syk and Btk, and additional downstream pathways that spread and amplify BCR signalling. B-lymphocyte development and function are also regulated by signals transduced through cell-surface molecules that include the CD19-CD21 signal transduction complex [3-51.
CD I 9 structure, expression and amplification of Src-family kinase activity CD19 is an approx. 95-kDa member of the immunoglobulin superfamily expressed exclusively on follicular dendritic cells and on B-cells during most stages of development until plasma cell differentiation. T h e approx. 240-amino-acid cytoplasmic domain of CD19 is critical for normal B-cell signalling [6, 7] . T h e cytoplasmic domains of human CD19 and mouse CD19 are highly homologous [8], allowing human CD19 to replace mouse CD19 function when expressed at the appropriate site density in CDl9-deficient (CD19-'-) mice [9] . CD19 cell-surface density is tightly regulated during B-cell development [9, 10] [7, 9, [15] [16] [17] 191 . Thus, CD19 regulates intrinsic B-lymphocyte signalling thresholds and also serves as a co-stimulatory molecule for amplifying BCR signalling. CD19 function intersects with multiple signalling pathways crucial for modulating intrinsic and antigen receptor-induced signals. T h e most significant function of CD19 is as a specialized adapter protein for the amplification of Src-family protein tyrosine kinase activity through a mechanism called ' processive amplification ' [3,20-221. Lyn that is activated endogenously or after BCR engagement is the primary kinase that phosphorylates CD19 [21] . After BCR or CD19 ligation, the binding of Lyn to phosphorylated CD19 results in amplified Lyn kinase activity [20] [21] [22] . CD19 phosphorylation and amplification of Lyn kinase activity facilitates CD19 interactions with Vav and the p85 subunit of phosphoinositide 3-kinase (PI 3-kinase), and initiates downstream events including the augmentation of intracellular calcium (Caf+) responses [20, . CD19 amplification of Lyn kinase activity is also required for optimal CD22 phosphorylation and activation of the CD22/SHP1 (SH2 domain-containing phosphotyrosine phosphatase 1) regulatory pathway [23] . CD22 phosphorylation also induces formation of a CD22-Shc-Grb-2 ternary complex that may downregulate Ca'+ responses through SH2-containing inositol polyphosphate 5-phosphatase recruitment [29] . As a consequence of these events, CD19 and BCR co-ligation dramatically lowers the threshold for B-cell activation in vitro [30, 31] , and regulates mitogen-activated protein kinase activation and proliferation [21, 30, 32] .
CD2 I structure, expression and function
T h e CD19-CD21 complex is composed of at least four non-covalently associated proteins : CD19, CD21 (complement receptor 2), CD81 and CD225 [33, 34] . CD21 is expressed on follicular dendritic cells and mature B-cells, with expression first by IgMhi/IgD1" transitional B-cells (cells with high levels of surface IgM and low levels of surface IgD) [35] . Cell-surface CD19 is present in molar excess of CD21 at all stages of B-cell development, although CD19 and CD21 are presumed to be present in a 1 : 1 ratio in CD19-CD21 complexes.
T h e CD21 extracellular domain is composed of 1 5 or 16 repeating structural elements that are termed short consensus repeats, a transmembrane region, and a 34-amino-acid cytoplasmic domain. CD21 and CD35 (complement receptor 1) are alternatively spliced products of the same CrZ gene in the mouse, but are encoded by different genes in humans [36, 37] . In the mouse, CD35 is generated by the addition of six short consensus repeats to the N-terminal end of the CD21 protein. T h e iC3b/C3d,g cleavage fragments of complement form covalent bonds with foreign antigens or immune complexes to generate C3d-antigen complexes that bind to CD21 [5] and signal through the CD19 complex (Figure 1) . Thus, C3d binding to CD21 supplies a well characterized ligand for the CD19 complex, thereby linking complement activation and B-cell signal transduction.
In two independent lines of (CD21/CD35)-'-mice, lymphocyte development, phenotypes and numbers are normal [38, 39] ; however, both lines exhibit impaired primary and secondary humoral immune responses and germinal centre formation, and they especially show inpaired IgG responses to T-cell-dependent antigens [38++0]. This does not result from defects in BCR signalling as (CD21/CD35)-'-B-cells respond normally to IgM and/or CD40 cross-linking [38] . Since the phenotype of (CD21/CD35)--mice is modest by comparison with that of CD19-'-mice, and since C D l 9 T G mice retain their hyper-responsive phenotype in the absence of CD21/CD35 or C3 expression, CD19 can regulate B-cell function independently of complement activation [41] ; however, at least one line of (CD21/CD35)--mice actually expresses a functionally active hypomorphic form of CD21/CD35, but at levels that are 6&70°/,, lower than in wild-type mice [41] . Therefore, the biological effects of complete CD21/CD35-deficiency may be unknown. Nevertheless, CD19, CD21 and C3 expression are interrelated and form a regulatory loop that influences B-cell function. Specifically, cell-surface CD19 and CD21 expression are significantly affected by the loss of CD21 and C3 expression respectively [41] . Mature B-cells from hypomorphic (CD21/ CD35)-'-mice have an approx. 36 O 0 higher cellsurface CD19 expression, while CD21/CD35 expression is increased by approx. 45 O 0 on B-cells from C3-j-mice. Negative regulation of CD19 and CD21 expression by CD21 and C3, respectively, may be functionally significant since small increases in cell-surface CD19 overexpression predisposes to autoimmunity. These results collectively demonstrate that CD21 engagement following complement activation may regulate the cell-surface density of CD19 and thereby indirectly regulate signalling thresholds.
C D I 9 expression regulates BCR-induced Ca:+ responses
BCR-induced Cap+ responses are accelerated and while CD19-'-mice have reduced and delayed Ca;+ responses ( Figure 2A ). CD19 engagement alone, using a dimeric mouse IgA anti-CD19 antibody, also induces dose-dependent increases in Ca;+ levels ( Figure 2B ) without the need for a cross-linking secondary antibody [42] . C D l 9 -induced Ca;+ responses are also augmented in B-cells that overexpress CD19. Thus, altered CD19 expression levels directly influence Ca;+ responses, even in the absence of CDl9-CD21 engagement by C3d-bearing immune complexes.
Maximal B-cell Ca;+ responses are induced either by simultaneous CD19 and BCR ligation [42] or following BCR and CD19 co-cross-linking [30, 43, 44] . In fact, B-cell Ca:+ responses are enhanced maximally by optimal IgM ligation in combination with suboptimal CD19 engagement ( Figure 2B ). We have, however, found recently that high-valency CD19 ligation inhibits BCRinduced Cat+ responses ( Figure 2B ). In fact, optimal CD19 ligation reduces BCR-induced Cat' responses to levels that are equivalent to CD19 ligation alone [42] . Similarly, optimal CD21 ligation inhibits BCR-induced Caf+ responses 1451. Thus, CD19 engagement can either augment or inhibit BCR-induced Caz+ responses and establish a balance between positive and negative regulatory signals depending on the extent, valency or timing of CD19 ligation [42] .
Mechanisms that regulate C D 19-and BCR-induced Caz+ responses
T h e ability of CD19 to modify Cat+ responses is likely to relate to its ability to amplify Src-family P T K activity, which complements BCR-induced augmented in B-cells that overexpress CD19, Lyn activation and subsequent activation of down- stream signalling pathways (Figure 1 ). In the absence of CD19 expression, Src P T K activity is not amplified, and this mutes and delays the initial phase of BCR-induced Caf+ responses. In addition, CD19-CD21 complex ligation alone results in enhanced formation of CD19-Lyn complexes and the translocation of CD19 into lipid rafts, regardless of concomitant BCR ligation [46, 47] . Thus, CD19 can transmit signals following CD21 ligation, as well as regulate CD21-independent signals. Enhanced Cat?+ responses by optimal IgM ligation with suboptimal C D l 9 engagement may also result from significantly augmented CDl9-Lyn complex formation with the amplification of BCR-induced Lyn activation (Figure 1 ). In addition, CD19 overexpression or simultaneous BCR and CD19 ligation inhibits downstream tyrosine phosphorylation of CD22 and multiple other cellular proteins, as well as SHPl recruitment to phosphorylated CD22 [42] . Thus, simultaneous CD19 and BCR engagement may sequester the available pool of functional Lyn away from downstream negative regulatory proteins, such as CD22. Consistent with this, CD22-'-and L y n P mice have augmented BCR-induced Caf+ responses [42, 48] , and simultaneous C D l 9 engagement does not further enhance the BCRinduced Caf+ responses of Lyn-or CD22-deficient B-cells.
High-valency CD19 or CD21 ligation may completely sequester the available pool of functional Lyn away from the BCR and downstream signalling events [42, 45] . Consistent with this, Syk and CD79a phosphorylation are not induced when CD19 is engaged using an anti-CD19 antibody at high concentrations [42] . Under these conditions, Lyn, Syk, and CD79a are only phosphorylated at levels equivalent to those induced by CD19 ligation alone. Thus, CD19 recruitment of Lyn and their preferential localization within lipid rafts may selectively activate signalling pathways downstream of the CDl9-Lyn complex, with the exclusion of other downstream regulatory and effector pathways. Therefore, small changes in the available pool of Lyn may be of profound importance since BCR, CD19-CD21 and Lyn cross-talk are precisely balanced to regulate Cat+ responses and normal B-cell function.
Our biochemical and genetic studies demonstrate that the CD19-CD21 complex interacts physically and shares overlapping pathways with multiple signalling molecules (Figure 1 ). Downstream effector molecules that participate in BCRand CD19-induced Caz+ responses include the Src-family P T K s (e.g. Lyn), Syk, phospholipase Cy, ). Although PI 3-kinase is recruited to the cell surface by multiple tyrosine-phosphorylated proteins, including CD19 [21, 25, 26] , CD19 expression is not required for PI 3-kinase activation following BCR ligation [49] . Likewise, Btk and CD19 interact physically, but BCR-and CD19-induced Caf+ responses appear to be more dependent on downstream Btk activation [49] . A concept of additive CD19 and Btk functions is also supported by the phenotype of Xid mice that lack CD19, where a combined CD19/Btk deficiency results in a more severe immunodeficiency. Therefore, the loss of CD19 does not inhibit either PI 3-kinase and Btk activation or Akt phosphorylation following BCR ligation; it does influence the time-course of these events, which are downstream of BCR and CD19 function (Figure 1 ).
Conclusions
In summary, cross-talk between the BCR, CD19-CD21, Lyn and Btk is titrated genetically [SO] , and is likely to be balanced precisely to regulate Caf+ responses and B-cell function. Moreover, the CD19-CD21 and BCR complexes can function and be regulated independently; however, both complexes play broad roles in regulating B-cell signalling thresholds and Ca;+ homoeostasis. Thus, functional interactions between the CD19 and BCR signalling pathways are likely to be dynamic and to be dependent on the activating stimuli and the state of B-cell maturation and activation. 
